Institut National De La Sante Et De La Recherche Medicale

Université Paul Sabatier (Toulouse III)

University College London

Centre Hospitalier Universitaire De Toulouse

Université De Caen Normandie

Centre Hospitalier Regional Universitaire De Caen

Romain Solinhac

Denis Vivien

Bart Vanhaesebroeck

Typhaine Anquetil

Gaëtan Chicanne

Aude Jaffre

Bernard Payrastre

Jean Darcourt

Vincent Larrue

Marie-Pierre Gratacap

Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.

Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity

Growing community of inventors

Toulouse, France

Romain Solinhac